X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Merck Ltd with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MERCK vs ASTRAZENECA PHARMA - Comparison Results

MERCK    Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    MERCK ASTRAZENECA PHARMA MERCK/
ASTRAZENECA PHARMA
 
P/E (TTM) x 56.7 118.0 48.1% View Chart
P/BV x 8.5 22.9 37.3% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 MERCK   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    MERCK
Dec-17
ASTRAZENECA PHARMA
Mar-18
MERCK/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,3581,278 106.2%   
Low Rs933883 105.7%   
Sales per share (Unadj.) Rs665.0228.4 291.2%  
Earnings per share (Unadj.) Rs56.610.4 545.9%  
Cash flow per share (Unadj.) Rs72.516.3 445.7%  
Dividends per share (Unadj.) Rs15.000-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs441.798.8 447.2%  
Shares outstanding (eoy) m16.6025.00 66.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.74.7 36.4%   
Avg P/E ratio x20.2104.2 19.4%  
P/CF ratio (eoy) x15.866.4 23.8%  
Price / Book Value ratio x2.610.9 23.7%  
Dividend payout %26.50-   
Avg Mkt Cap Rs m19,01127,008 70.4%   
No. of employees `0001.51.4 113.9%   
Total wages/salary Rs m1,6961,535 110.5%   
Avg. sales/employee Rs Th7,150.04,210.9 169.8%   
Avg. wages/employee Rs Th1,098.71,132.2 97.0%   
Avg. net profit/employee Rs Th608.2191.1 318.3%   
INCOME DATA
Net Sales Rs m11,0405,710 193.3%  
Other income Rs m240123 195.7%   
Total revenues Rs m11,2795,833 193.4%   
Gross profit Rs m1,376463 297.3%  
Depreciation Rs m264147 179.1%   
Interest Rs m00-   
Profit before tax Rs m1,352438 308.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1700-   
Tax Rs m583179 325.8%   
Profit after tax Rs m939259 362.4%  
Gross profit margin %12.58.1 153.8%  
Effective tax rate %43.140.8 105.5%   
Net profit margin %8.54.5 187.5%  
BALANCE SHEET DATA
Current assets Rs m7,5233,209 234.4%   
Current liabilities Rs m2,2532,070 108.8%   
Net working cap to sales %47.720.0 239.2%  
Current ratio x3.31.6 215.4%  
Inventory Days Days5272 72.1%  
Debtors Days Days4135 116.1%  
Net fixed assets Rs m1,240790 156.9%   
Share capital Rs m16650 332.0%   
"Free" reserves Rs m7,1672,419 296.2%   
Net worth Rs m7,3332,469 297.0%   
Long term debt Rs m00-   
Total assets Rs m9,9124,605 215.2%  
Interest coverage xNMNM-  
Debt to equity ratio x00-  
Sales to assets ratio x1.11.2 89.8%   
Return on assets %9.55.6 168.4%  
Return on equity %12.810.5 122.1%  
Return on capital %20.817.7 117.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,015300 338.7%   
Fx outflow Rs m3,0432,015 151.0%   
Net fx Rs m-2,028-1,715 118.2%   
CASH FLOW
From Operations Rs m53788 610.5%  
From Investments Rs m-476-94 508.9%  
From Financial Activity Rs m-220NA-  
Net Cashflow Rs m-160-6 2,798.2%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 51.8 75.0 69.1%  
Indian inst/Mut Fund % 18.2 0.3 6,066.7%  
FIIs % 1.0 15.7 6.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 9.1 319.8%  
Shareholders   28,591 12,856 222.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare MERCK With:   CIPLA  PFIZER  ALKEM LABORATORIES  SUN PHARMA  SANOFI INDIA  

Compare MERCK With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Higher; Oil & Gas Stocks Gain(09:30 am)

Asian stock markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.3% while the Hang Seng is down 0.4%.

Related Views on News

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

MERCK LTD Announces Quarterly Results (3QFY19); Net Profit Up 31.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, MERCK LTD has posted a net profit of Rs 135 m (up 31.3% YoY). Sales on the other hand came in at Rs 2 bn (down 32.8% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 66.7% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 91 m (down 66.7% YoY). Sales on the other hand came in at Rs 2 bn (down 1.8% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

MERCK LTD Announces Quarterly Results (2QFY19); Net Profit Up 29.8% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, MERCK LTD has posted a net profit of Rs 411 m (up 29.8% YoY). Sales on the other hand came in at Rs 2 bn (down 27.7% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

More Views on News

Most Popular

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

My Master Series on How to Trade Election 2019(Profit Hunter)

Apr 16, 2019

For 30 years he has watched how elections impact the markets, and practiced how to profit from it. Now he is here...telling you everything. Read on...

A Simple 3-Point Investing Manifesto for You the Indian Investor(The 5 Minute Wrapup)

Apr 11, 2019

A must have checklist for every investor in the Indian stock market.

Election Series: Follow the World's Biggest Traders To See Where the Money Flows(The 5 Minute Wrapup)

Apr 17, 2019

20% of all the traders bring in 80% of the money. Watch these 20% and you get a working idea of which way the wind is blowing.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

MERCK SHARE PRICE


Apr 24, 2019 09:53 AM

TRACK MERCK

MERCK - PIRAMAL ENTERPRISES COMPARISON

COMPARE MERCK WITH

MARKET STATS